PAP Device Coverage Criteria

PAP device coverage criteria: Positive airway pressure (PAP) devices (CPAP, APAP, APAP with pressure relief, and BiPAP without backup rate when indicated) are considered medically necessary DME when objective sleep testing meets policy AHI/RDI thresholds and scoring rules (AHI/RDI ≥15 events/hr with ≥30 events, or AHI/RDI 5–14.9 events/hr with ≥10 events plus qualifying comorbidity or symptoms). Home sleep test minimum recording and event-count rules apply; indexes that include non‑AHI/RDI events (eg, RERAs, leg movement) are not acceptable for PAP authorization. Replacement is covered at end of a 5‑year reasonable useful lifetime or sooner for clinical change; replacements due to misuse or abuse are not covered.

• PAP types covered: CPAP, CPAP with pressure relief, APAP, APAP with pressure relief; BiPAP/DPAP/VPAP when CPAP/APAP intolerant or ineffective and criteria documented
• Sleep test requirements: minimum recording rules, event count thresholds, AHI vs RDI definitions and acceptable device types (Type I–IV, WatchPAT)
• Replacement rules: 5‑year RUL; earlier replacement only for clinical change; misuse/abuse excluded

Prior Authorization Not Stated Explicitly Here (Operational Note)

Prior authorization: The policy text does not stipulate a single, universal prior authorization (PA) requirement for all procedures/devices in this section. Providers should follow payer-specific PA procedures where listed elsewhere. Where implants, neurostimulators, and some surgeries are subject to utilization review or medical necessity review, prior authorization is recommended to confirm selection criteria are met before implantation or device dispensing.

• No single PA statement in this excerpt — follow payer PA processes
• PA is recommended for implants and device-based therapies to confirm criteria and avoid denials

Prior Authorization Recommended for Implants and Implantable Neurostimulators

Prior authorization recommended for implants/devices: For implanted neurostimulators (hypoglossal nerve stimulators/UAS), implanted leads/generators, and newer implantable or procedural devices (eg, tongue‑suspension anchors, palatal implants, glossectomy‑related implants), obtain prior authorization or pre‑service medical review to ensure FDA labeling, selection criteria, and documentation (PSG, DISE, BMI limits, prior CPAP trial) are met.

• HCPCS/LT codes for implantable neurostimulator components require selection criteria to be met (see coding section)
• Confirm FDA approved indication and up‑to‑date BMI/AHI limits prior to implantation

Device Clearance and FDA Labeling — Operational Reminder

Device clearance note: Many devices described (CPAP, home sleep monitors, oral appliances, Lunoa, eXciteOSA, Inspire UAS, Lunoa positional systems, Elevo, ULTepap) have FDA 510(k) clearance or specific FDA approvals; clearance status does not by itself establish clinical effectiveness for all indications. Verify device-specific FDA labeling and approved indications when evaluating coverage.

• 510(k) clearance common for many home sleep and oral devices
• Some devices (Inspire UAS, Lunoa, eXciteOSA) have FDA approvals/clearances with specific labeled indications and contraindications

Prior Authorization: Match UAS Trial/Label Selection Criteria

Prior authorization to match trial selection criteria for UAS: Prior to UAS implantation, ensure documentation aligns with trial/label selection criteria: age, BMI threshold, PSG results within required timeframe, predominance of obstructive events, prior CPAP failure/intolerance documented, and DISE demonstrating absence of complete concentric collapse.

• PSG within timeframe (eg, within 24 months of first consultation historically; check current device labeling)
• AHI/ODI ranges per device labeling (device-specific: e.g., Inspire expanded to AHI up to 100 and BMI up to 40 in recent FDA updates)
• Document CPAP failure (AHI > device‑specified threshold on CPAP) or CPAP intolerance (<4 hrs/night on ≥5 nights/week)

Prior Authorization: Confirm FDA Labeling and Selection Criteria

Prior authorization: confirm FDA labeling and selection criteria — for hypoglossal nerve stimulation and other device implants, prior authorization (or medical review) should confirm current FDA‑cleared/approved AHI and BMI ranges, contraindications, MRI labeling, and any device‑specific requirements (eg, requirement for DISE).

• Confirm current FDA AHI and BMI thresholds (updates have occurred)
• Confirm MRI labeling and any device contraindications prior to implant

Oral Appliance Devices and FDA Status — Documentation Expectations

Oral appliance devices and FDA status: Oral appliances (mandibular advancement devices, tongue retainers, Silent Partner, Snore Guard, Slow Wave DS8) may be FDA‑cleared (510(k)) or marketed as Class II devices. Oral appliances are generally considered a second‑line alternative to CPAP for patients intolerant of CPAP. Document device type (custom vs prefabricated) and clinical rationale for use.

• Oral appliances effective for mild‑to‑moderate OSA; less reliable than CPAP
• Document prior CPAP intolerance when using oral appliances as alternative

DISE Required for UAS Candidacy Evaluation

DISE required for UAS candidacy evaluation: Drug‑induced sleep endoscopy (DISE) is required per FDA‑approved UAS selection criteria to document absence of complete concentric collapse at the velum; DISE may be considered investigational for other indications. DISE findings (VOTE classification) should be documented in the record.

• DISE must document absence of complete concentric velopharyngeal collapse for UAS candidacy
• Record DISE using VOTE classification where possible

Positional Therapy Devices — Prior Authorization Considerations

Positional therapy device prior authorization: For newer positional therapy systems (eg, Lunoa, Sleep Position Trainer, Lunoa System), verify FDA clearance/indications and consider prior authorization when the device is being requested as an alternative to CPAP; ensure positional OSA criteria are documented (non‑supine AHI <20 and positional dependence).

• Lunoa cleared for positional OSA with non‑supine AHI <20 (510k) — document positional dependence
• Consider PA to confirm that positional therapy is appropriate and less‑invasive options attempted or contraindicated

eXciteOSA — Prior Authorization Considerations

eXciteOSA: prior authorization considerations: eXciteOSA is FDA‑cleared for daytime neuromuscular tongue stimulation in mild OSA and snoring. When requesting coverage, document indication (AHI 5–15 for mild OSA), patient age, exclusions (BMI limits, dental conditions, pacemaker/implanted electrical device), and expected treatment course (20 minutes/day for 6 weeks, then maintenance). Consider PA to confirm candidacy and that alternatives were considered.

• FDA clearance limited to adults with mild OSA and snoring (AHI 5–15)
• Document WatchPAT or equivalent baseline AHI and inclusion/exclusion criteria met

PAP Supplies — Quantities and Intervals

PAP supplies quantities and intervals: Follow the policy’s usual medically necessary quantities and replacement intervals for PAP supplies (eg, tubing, masks, cushions, filters, headgear, chinstraps). Ensure supply requests align with the listed frequencies (monthly, quarterly, semiannual) and do not exceed policy limits.

• Examples: tubing/heated tubing — 1 per 3 months; full face mask — 1 per 3 months; cushion replacements — typically 2 per month; headgear — 1 per 6 months; filters — disposable 2 per month

Invalid AHI/RDI Basis — Potential Denial

Invalid AHI/RDI basis — denial risk: Requests based on an AHI/RDI calculated from indices that include non‑AHI events (eg, leg movements, RERAs not separated) or derived from too short a recording or insufficient event count are not acceptable and may be denied. Ensure sleep study meets minimum recording duration and event‑count rules per policy.

• AHI/RDI must be calculated per policy definitions and minimum recording/event counts met
• Projections from short recordings or indices counting REM‑only events are unacceptable

Replacement Exclusion — Coverage Limitation

Replacement exclusion: Replacement of PAP devices required because of misuse or abuse is not covered. Replacement coverage is limited to end of 5‑year reasonable useful lifetime or earlier only for documented clinical need/change.

• Document reason for replacement (end of RUL vs clinical change)
• Replacements for misuse/abuse will be denied

Noncovered Device/Service Triggers — Check Coding Table

Noncovered device/service triggers: Certain devices and CPT/HCPCS codes (eg, Zzoma positional device HCPCS E0190, specified palatal and experimental device codes, some surgical codes when criteria not met) are listed as not covered for indications in the policy. Verify coding against the policy’s coding tables and ensure medical necessity criteria are documented for covered surgical codes.

• Zzoma positional device (E0190) listed as not medically necessary
• Specific CPT/HCPCS/ICD‑10 codes in the coding section flagged as not covered when criteria not met

ASV and Bilevel with Backup Rate — Investigational for OSA

ASV / bilevel with backup rate investigational: Adaptive servo‑ventilation (ASV) and bilevel devices with a backup rate feature are considered experimental/investigational for OSA (consistent with DME MAC guidance) and are not medically necessary for routine OSA treatment.

• ASV/backup‑rate bilevel devices use (eg, VPAP Adapt) is investigational for OSA indications
• Considered only per specific non‑OSA indications consistent with coverage rules

Palatal Implants — Evidence Insufficiency and Denial Risk

Palatal implants — evidence insufficiency: Palatal implants (eg, Pillar system, other soft‑palate implants) have limited and inconsistent evidence; several technology assessments recommend against routine use. Coverage is unlikely without strong, case‑specific evidence; prior authorization and review recommended.

• CADTH and NICE concluded inadequate evidence to support routine palatal implant use for OSA
• Randomized trials show mixed/limited benefit and device‑related risks (eg, partial extrusion)

Selection‑Related Exclusion Risks — Watch for Denial Triggers

Selection‑related exclusion risks: Device/surgical candidacy exclusions (eg, BMI thresholds, neuromuscular disease, severe cardiopulmonary disease, large tonsils, pacemaker considerations for some devices) identified in trials and device labeling may lead to denial if patient falls outside selection criteria.

• Examples: historical UAS trial exclusions included BMI >32 (labeling updated over time); other exclusions include neuromuscular disease, hypoglossal palsy, severe pulmonary hypertension, recent MI
• Check device labeling and trial criteria for current BMI and comorbidity cutoffs

Contraindicating Conditions May Lead to Denial

Contraindicating conditions that may lead to denial: Documented complete concentric collapse of the velum on DISE, significant anatomic findings (eg, tonsil size 3–4 for some devices), active psychiatric disease, pregnancy, lack of ability to operate device programmer, and other contraindications per device labeling can render a patient ineligible for implantable neurostimulation or specific device use.

• Absence of complete concentric collapse is required for UAS candidacy — presence may lead to denial
• Document other anatomical or functional contraindications noted in device labeling

Limited Evidence May Lead to Denial for Emerging Procedures/Devices

Evidence insufficiency risk for many pharyngeal surgeries and novel devices: Many pharyngeal surgeries, novel palatal expansion techniques, and emerging devices (tongue anchors, NightLase LAUP, EASE, Elevo, Slow Wave DS8) have limited high‑quality evidence; requests for coverage should include robust pre‑ and post‑operative objective metrics and may be subject to denial if evidence is insufficient.

• Multi‑level surgery evidence often level 4 (case series) — careful selection and documentation needed
• Emerging technologies frequently lack long‑term comparative data

DISE and UAS Evaluation — Operational Note

DISE and UAS evaluation — operational note: DISE is part of UAS evaluation and should be documented using standardized descriptors (eg, VOTE). Inter‑rater variability exists; include DISE video/report in pre‑authorization materials when available.

• Include DISE report/video and VOTE classification when requesting UAS coverage
• Note potential variability in DISE interpretation and include supporting PSG/clinical data

Device Indication and Evidence — Documentation Expectations

Device indication and evidence (Lunoa, positional devices, SPT, ULTepap): For positional devices and other new devices (Lunoa, SPT, ULTepap), document positional dependence, baseline PSG/WatchPAT metrics, device‑specific AHI cutoffs (eg, Lunoa non‑supine AHI <20), and patient adherence/response metrics. FDA clearance does not equate to robust long‑term effectiveness.

• Document baseline non‑supine and supine AHI and device‑measured positional data where available
• Provide short‑term objective outcomes and adherence data when seeking coverage

Novel Interventions — Limited Evidence May Result in Denial

Limited evidence may lead to denial for novel interventions: For procedures such as EASE, elevoplasty/Elevo, NightLase LAUP, Slow Wave DS8, and other minimally invasive interventions, the current evidence base is limited and often retrospective or small‑scale; prior authorization with robust clinical justification is recommended and claims may be denied if evidence for effectiveness is not provided.

• Provide peer‑reviewed outcomes, PSG changes, and safety data when requesting coverage for novel interventions
• Expect medical review for small uncontrolled study–based justifications

Hypoglossal Stimulation — Required Documentation

Hypoglossal stimulation documentation: For hypoglossal nerve stimulation/UAS requests, include age, BMI, PSG (AHI/ODI) within device timeframe, DISE findings (absence of complete concentric collapse), documentation of predominant obstructive events (<25% central/mixed), objective CPAP trial data showing failure or intolerance, and informed consent regarding device risks/benefits.

• PSG within labeled timeframe (eg, historically 24 months) and device‑specified AHI/ODI limits
• Document CPAP monitoring: failure (AHI remains elevated on CPAP) or intolerance (<4 hrs/night on ≥5 nights/week)

CPAP Trial Monitoring — Objective Documentation Required

CPAP trial monitoring: Document objective CPAP adherence and effectiveness using compliance downloads (smart card, device reports). Adherence defined as ≥4 hours/night on ≥70% of nights over a consecutive 30‑day period (policy definition for continued use); UAS and other device trials require documentation of CPAP failure or intolerance per device criteria.

• Include device compliance report showing hours/night and percent nights
• For UAS: document CPAP failure (AHI above device threshold despite CPAP) or documented intolerance (<4 hrs/night on 5 nights/week)

Required Outcome Measurements for Device/Surgical Interventions

Required outcome measurements: Authorizations and continued coverage decisions should include objective outcome measures when applicable — PSG AHI/ODI, oxygen desaturation index (ODI), Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), and device‑measured adherence. Provide baseline and follow‑up measures to demonstrate clinical benefit.

• Common metrics: AHI, ODI, ESS, FOSQ, percent time <90% O2 saturation
• Include pre‑ and post‑intervention PSGs or device‑measured outcomes where available

Pre‑Implantation Documentation Required

Required pre‑implantation documentation: For implantable devices (UAS, neurostimulators), submit pre‑implantation PSG, DISE report, CPAP trial documentation, BMI and comorbidity assessment, and any device‑specific screening results. Ensure documentation aligns with published trial inclusion/exclusion criteria and current FDA labeling.

• Pre‑implant PSG and DISE (VOTE) required for UAS requests
• Document prior CPAP trial and objective compliance/titration data

Pre‑operative DISE and PSG — Documentation Expectations

Pre‑op DISE and PSG: When surgery or implant is being considered, include full PSG and DISE in the pre‑operative evaluation as used in pivotal studies. DISE should document the pattern and level(s) of collapse; PSG should provide baseline AHI/ODI and oxygenation metrics.

• DISE and PSG reports improve selection and predict surgical outcomes
• Use standardized scoring (VOTE) for DISE where possible

Required Outcome Documentation for Surgical Expansion Procedures

Required clinical documentation for surgical expansion and other surgeries: For procedures such as palatopharyngoplasty, jaw realignment, EASE, glossectomy, and palatal expansion, include documentation of prior CPAP trials, objective baseline PSG, anatomic findings supporting surgery, surgical plan, and post‑operative PSG or objective outcome measures to support medical necessity.

• Palatopharyngoplasty requires documented prior CPAP/AutoPAP attempt and intolerance/failure
• Jaw realignment often requires multi‑disciplinary review and documentation that less‑invasive options failed

Required Clinical Documentation for Testing

Required clinical documentation for testing: For diagnostic testing (home or facility PSG/HSAT), document clinical features (eg, ESS >10, BMI >30, witnessed apneas, daytime sleepiness while driving) that meet indications for testing, and ensure test type and scoring meet policy definitions. Repeat testing for equipment replacement alone is not medically necessary unless other policy criteria are met.

• Appendix indications: ESS ≥10, BMI >30, witnessed apnea, excessive sleepiness while driving
• Repeat sleep testing for replacement CPAP equipment is not medically necessary absent other indications

Step Therapy — CPAP First‑Line; Prior CPAP Trial Required Before Surgery/Alternatives

Step requirement before palatopharyngoplasty and require prior CPAP trial for alternatives: Surgical interventions (eg, UPPP/palatopharyngoplasty) and alternatives (oral appliances, surgery, neurostimulation) are expected to follow a stepwise approach with CPAP as first‑line; document attempted CPAP (titration, mask adjustments) and objective failure or intolerance before elective pharyngeal surgery.

• Document CPAP attempts, mask/interface optimization, and objective adherence/response before surgery
• CPAP is first‑line; bilevel/other modalities reserved as second‑line when CPAP intolerant or ineffective

CPAP Trial Required; UAS Considered Second‑Line

Require prior trial/intolerance of CPAP; UAS as second‑line after CPAP: Upper airway stimulation and many surgical/device alternatives are second‑line therapies for patients who fail or are intolerant of CPAP. Document objective CPAP failure (persistently elevated AHI on CPAP) or intolerance (insufficient usage) before considering UAS or other invasive options.

• UAS is indicated as second‑line for patients unable or unwilling to use CPAP with demonstrated failure/intolerance
• Provide objective CPAP compliance/download data

Stepwise Management — Neurostimulation After Less‑Invasive Options

Step therapy consideration for neurostimulation vs less‑invasive options: Consider less‑invasive options (CPAP optimization, oral appliances, positional therapy) before neurostimulation when clinically appropriate. For neurostimulation, ensure prior steps are documented and clinical rationale for progression to implantable therapy is clear.

• Document trials of less‑invasive therapies and reasons for progression to implanted neurostimulation
• Include objective outcome measures from prior therapies

No Universal Step Therapy Narrative for All Novel Devices (Operational Note)

No explicit step therapy requirements provided in this excerpt for some novel devices: While the policy emphasizes CPAP first‑line and documents stepwise management for many interventions, it does not lay out uniform mandatory step therapy sequences for all novel devices; use clinical judgment and payer PA rules when sequencing therapies.

• Check payer‑specific step therapy or PA policies for device sequencing
• Document clinical rationale when deviating from typical stepwise approach

Stepwise Management Before Novel Interventions — Documentation Recommended

Stepwise management before novel interventions: For emerging technologies and novel interventions (eg, elevoplasty, TES/TENS, EASE, Slow Wave DS8), document prior conventional therapy attempts, objective metrics of failure or intolerance, and provide study evidence or registries where available to support medical necessity.

• Provide evidence of prior CPAP/oral appliance/positional therapy trials where applicable
• Include prospective outcome data or trial evidence when requesting coverage for novel interventions